tousled1
12-16-2007, 12:52 PM
SAN ANTONIO, Dec. 16 -- The consensus that tamoxifen is limited to a five-year therapeutic lifetime against a recurrence of breast cancer is flawed, found a major international trial that suggests longer treatment is better
To read full article: http://www.medpagetoday.com/MeetingCoverage/SABCSMeeting/tb/7715
To read full article: http://www.medpagetoday.com/MeetingCoverage/SABCSMeeting/tb/7715